← Back to Clinical Trials
Recruiting NCT04661059

NCT04661059 Study of Late-foetal Human Organ Development

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04661059
Status Recruiting
Phase
Sponsor University College London Hospitals
Condition Congenital Disorders
Study Type OBSERVATIONAL
Enrollment 2,000 participants
Start Date 2022-02-03
Primary Completion 2024-09-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 2,000 participants in total. It began in 2022-02-03 with a primary completion date of 2024-09-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Knowledge about abnormal organ development is important to understand pathology and to develop novel treatment approaches for individuals with congenital and acquired disease. Most of our current understanding is based on examination of tissues from the embryo and early fetus, collected from women undergoing termination of pregnancy in the first trimester (third) of pregnancy. There is very little known about normal and abnormal organ development from a developmental perspective during the crucial last two-thirds of pregnancy when much remodelling of fetal tissues occurs. We aim to collect tissue from a variety of developing fetal organs in the last two-thirds of pregnancy from women who decide to undergo a termination of pregnancy and who wish to undergo a clinical fetal postmortem (PM) examination.

Eligibility Criteria

Inclusion Criteria: * ≥18 years old pregnant women who attend the Fetal Medicine Unit for concerns about a fetal abnormality where they decide to proceed to termination of pregnancy Exclusion Criteria: * Screening labs positive for maternal HIV, Hepatitis B and Hepatitis C, Chlamydia and Herpes. * Subject unable to make an informed decision about termination of pregnancy.

Contact & Investigator

Central Contact

Sarah Gibbon

✉ sarah.gibbon1@nhs.net

📞 +44 20 3456 7890

Frequently Asked Questions

Who can join the NCT04661059 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Congenital Disorders. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04661059 currently recruiting?

Yes, NCT04661059 is actively recruiting participants. Contact the research team at sarah.gibbon1@nhs.net for enrollment information.

Where is the NCT04661059 trial being conducted?

This trial is being conducted at London, United Kingdom.

Who is sponsoring the NCT04661059 clinical trial?

NCT04661059 is sponsored by University College London Hospitals. The trial plans to enroll 2,000 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology